|
Clinical efficacy rates
|
Overall analysis |
7 (15–18,24,25,27) |
1.29 [1.17, 1.42] |
<0.0001 |
| Excluding studies with low quality |
6 (15,17,18,25,27) |
1.33 [1.19, 1.49] |
<0.0001 |
| Excluding small trial (participants < 50) |
6 (15–17,24,25,27) |
1.26 [1.15, 1.39] |
<0.0001 |
| Excluding the lagest trial |
6 (15,17,18,25,27) |
1.33 [1.19, 1.49] |
<0.0001 |
| Excluding studies containing TCM |
2 (18,27) |
1.56 [1.17, 2.07] |
0.002 |
| Using random-effects model |
7 (15–18,24,25,27) |
1.25 [1.14, 1.37] |
<0.0001 |
|
Sensitivity analyses
|
No. of included trials (reference nos.)
|
SMD [95% CI]
|
P
|
|
BCVA
|
Overall analysis |
5 (16–18,23,25) |
0.95 [0.26,1.64] |
0.007 |
| Excluding studies with low quality |
4 (16–18,23) |
0.99 [0.09, 1.89] |
0.03 |
| Excluding small trial (participants < 50) |
4 (16,17,23,25) |
1.15 [0.38, 1.92] |
0.003 |
| Excluding the lagest trial |
3 (17,18,23,25) |
1.09 [0.24, 1.95] |
0.01 |
| Excluding studies containing TCM |
3 (16,17,25) |
0.76 [0.34, 1.18] |
0.0004 |
| Using fixed-effects model |
5 (16–18,23,25) |
0.88 [0.65, 1.12] |
<0.0001 |
|
Sensitivity analyses
|
No. of included trials (reference nos.)
|
MD [95% CI]
|
P
|
|
CMT
|
Overall analysis |
3(16–18) |
-32.74 [-60.94, -4.55] |
0.02 |
| Excluding studies with low quality |
2 (17,18) |
-31.69 [-71.37, 7.99] |
0.12 |
| Excluding small trial (participants < 50) |
2 (17,18) |
-31.69 [-71.37, 7.99] |
0.12 |
| Excluding the lagest trial |
2 (16,17) |
-48.36 [-61.90, -34.81] |
<0.0001 |
| Excluding studies containing TCM |
1 (18) |
-32.60 [-77.59, 12.39] |
0.16 |
| Using fixed-effects model |
3(16–18) |
-41.49 [-53.79, -29.19] |
<0.0001 |
